Ajila, Vidya, Harish Shetty, Subhas Babu, Veena Shetty, and Shruthi Hegde, ‘Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck’, Journal of Sexually Transmitted Diseases, 2015 (2015), 1–5 <https://doi.org/10.1155/2015/791024>
Barrett, David M., Stephan A. Grupp, and Carl H. June, ‘Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street’, The Journal of Immunology, 195.3 (2015), 755–61 <https://doi.org/10.4049/jimmunol.1500751>
Ecker, Dawn M, Susan Dana Jones, and Howard L Levine, ‘The Therapeutic Monoclonal Antibody Market’, mAbs, 7.1 (2015), 9–14 <https://doi.org/10.4161/19420862.2015.989042>
Gill, Saar, and Carl H. June, ‘Going Viral: Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies’, Immunological Reviews, 263.1 (2015), 68–89 <https://doi.org/10.1111/imr.12243>
Grupp, Stephan A., Michael Kalos, David Barrett, Richard Aplenc, David L. Porter, Susan R. Rheingold, and others, ‘Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia’, New England Journal of Medicine, 368.16 (2013), 1509–18 <https://doi.org/10.1056/NEJMoa1215134>
Hanahan, Douglas, and Robert A Weinberg, ‘The Hallmarks of Cancer’, Cell, 100.1 (2000), 57–70 <https://doi.org/10.1016/S0092-8674(00)81683-9>
zur Hausen, Harald, ‘Papillomaviruses in the Causation of Human Cancers — a Brief Historical Account’, Virology, 384.2 (2009), 260–65 <https://doi.org/10.1016/j.virol.2008.11.046>
Hodi, F. Stephen, Steven J. O’Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B. Haanen, and others, ‘Improved Survival with Ipilimumab in Patients with Metastatic Melanoma’, New England Journal of Medicine, 363.8 (2010), 711–23 <https://doi.org/10.1056/NEJMoa1003466>
Jeggo, Penny A., Laurence H. Pearl, and Antony M. Carr, ‘DNA Repair, Genome Stability and Cancer: A Historical Perspective’, Nature Reviews Cancer, 16.1 (2015), 35–42 <https://doi.org/10.1038/nrc.2015.4>
Kaufman, Howard L., Frederick J. Kohlhapp, and Andrew Zloza, ‘Oncolytic Viruses: A New Class of Immunotherapy Drugs’, Nature Reviews Drug Discovery, 14.9 (2015), 642–62 <https://doi.org/10.1038/nrd4663>
Klebanoff, Christopher A, Steven A Rosenberg, and Nicholas P Restifo, ‘Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers’, Nature Medicine, 22.1 (2016), 26–36 <https://doi.org/10.1038/nm.4015>
Koebel, Catherine M., William Vermi, Jeremy B. Swann, Nadeen Zerafa, Scott J. Rodig, Lloyd J. Old, and others, ‘Adaptive Immunity Maintains Occult Cancer in an Equilibrium State’, Nature, 450.7171 (2007), 903–7 <https://doi.org/10.1038/nature06309>
Larson, Christopher, Bryan Oronsky, Jan Scicinski, Gary R. Fanger, Meaghan Stirn, Arnold Oronsky, and others, ‘Going Viral: A Review of Replication-Selective Oncolytic Adenoviruses’, Oncotarget, 6.24 (2015) <https://doi.org/10.18632/oncotarget.5116>
Lazebnik, Yuri, ‘What Are the Hallmarks of Cancer?’, Nature Reviews Cancer, 10.4 (2010), 232–33 <https://doi.org/10.1038/nrc2827>
Lingyun Geng, ‘Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Experimental and Clinical Developments’, International Journal of Clinical and Experimental Medicine, 8.9 (2015) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/>
de Martel, Catherine, Jacques Ferlay, Silvia Franceschi, Jérôme Vignat, Freddie Bray, David Forman, and others, ‘Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis’, The Lancet Oncology, 13.6 (2012), 607–15 <https://doi.org/10.1016/S1470-2045(12)70137-7>
Matsuoka, M, and K-T Jeang, ‘Human T-Cell Leukemia Virus Type 1 (HTLV-1) and Leukemic Transformation: Viral Infectivity, Tax, HBZ and Therapy’, Oncogene, 30.12 (2011), 1379–89 <https://doi.org/10.1038/onc.2010.537>
Morris, Emma C., and Hans J. Stauss, ‘Optimizing T-Cell Receptor Gene Therapy for Hematologic Malignancies’, Blood, 127.26 (2016), 3305–11 <https://doi.org/10.1182/blood-2015-11-629071>
Palucka, Karolina, and Jacques Banchereau, ‘Cancer Immunotherapy via Dendritic Cells’, Nature Reviews Cancer, 12.4 (2012), 265–77 <https://doi.org/10.1038/nrc3258>
Pierangeli, A., G. Antonelli, and G. Gentile, ‘Immunodeficiency-Associated Viral Oncogenesis’, Clinical Microbiology and Infection, 21.11 (2015), 975–83 <https://doi.org/10.1016/j.cmi.2015.07.009>
Reichert, Janice M., ‘Antibodies to Watch in 2016’, mAbs, 8.2 (2016), 197–204 <https://doi.org/10.1080/19420862.2015.1125583>
———, ‘Antibodies to Watch in 2017’, mAbs, 9.2 (2017), 167–81 <https://doi.org/10.1080/19420862.2016.1269580>
———, ‘Marketed Therapeutic Antibodies Compendium’, mAbs, 4.3 (2012), 413–15 <https://doi.org/10.4161/mabs.19931>
Restifo, Nicholas P., Mark E. Dudley, and Steven A. Rosenberg, ‘Adoptive Immunotherapy for Cancer: Harnessing the T Cell Response’, Nature Reviews Immunology, 12.4 (2012), 269–81 <https://doi.org/10.1038/nri3191>
Robbins, Paul F., Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, and others, ‘Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1’, Journal of Clinical Oncology, 29.7 (2011), 917–24 <https://doi.org/10.1200/JCO.2010.32.2537>
Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth, ‘Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion’, Science, 331.6024 (2011), 1565–70 <http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents>
Roos, Wynand P., Adam D. Thomas, and Bernd Kaina, ‘DNA Damage and the Balance between Survival and Death in Cancer Biology’, Nature Reviews Cancer, 16.1 (2015), 20–33 <https://doi.org/10.1038/nrc.2015.2>
Russell, Stephen J, Kah-Whye Peng, and John C Bell, ‘Oncolytic Virotherapy’, Nature Biotechnology, 30.7 (2012), 658–70 <https://doi.org/10.1038/nbt.2287>
Schinzari, V., V. Barnaba, and S. Piconese, ‘Chronic Hepatitis B Virus and Hepatitis C Virus Infections and Cancer: Synergy between Viral and Host Factors’, Clinical Microbiology and Infection, 21.11 (2015), 969–74 <https://doi.org/10.1016/j.cmi.2015.06.026>
Schumacher, T. N., and R. D. Schreiber, ‘Neoantigens in Cancer Immunotherapy’, Science, 348.6230 (2015), 69–74 <https://doi.org/10.1126/science.aaa4971>
Shankaran, Vijay, Hiroaki Ikeda, Allen T. Bruce, J. Michael White, Paul E. Swanson, Lloyd J. Old, and others, ‘IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity’, Nature, 410.6832 (2001), 1107–11 <https://doi.org/10.1038/35074122>
Spurgeon, Megan E., and Paul F. Lambert, ‘Merkel Cell Polyomavirus: A Newly Discovered Human Virus with Oncogenic Potential’, Virology, 435.1 (2013), 118–30 <https://doi.org/10.1016/j.virol.2012.09.029>
Topalian, Suzanne L., F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David C. Smith, David F. McDermott, and others, ‘Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer’, New England Journal of Medicine, 366.26 (2012), 2443–54 <https://doi.org/10.1056/NEJMoa1200690>
Varghese, Susan, and Samuel D Rabkin, ‘Oncolytic Herpes Simplex Virus Vectors for Cancer Virotherapy’, Cancer Gene Therapy, 9.12 (2002), 967–78 <https://doi.org/10.1038/sj.cgt.7700537>
Weinberg, Robert A., The Biology of Cancer, 2nd ed (New York: Garland Science, 2014)
Weiss, Robin A., and Peter K. Vogt, ‘100 Years of Rous Sarcoma Virus’, The Journal of Experimental Medicine, 208.12 (2011), 2351–55 <https://doi.org/10.1084/jem.20112160>
Wendzicki, Justin A, Patrick S Moore, and Yuan Chang, ‘Large T and Small T Antigens of Merkel Cell Polyomavirus’, Current Opinion in Virology, 11 (2015), 38–43 <https://doi.org/10.1016/j.coviro.2015.01.009>
